India is expected to continue allowing over-the-counter (OTC) sales of levonorgestrel-based morning-after pills, despite earlier regulatory concerns. Health experts and gynecologists support the move, citing its role in reducing adolescent pregnancies and improving reproductive autonomy, especially for young women with limited access to confidential medical care.
India’s drug regulatory authorities are leaning toward maintaining over-the-counter availability of emergency contraceptive pills, popularly known as morning-after pills. The decision comes amid growing concerns over adolescent pregnancies and limited access to reproductive health services for young women.
Earlier, the Central Drugs Standard Control Organisation (CDSCO) had considered restricting OTC sales of hormonal contraceptives, including levonorgestrel-based pills, by reclassifying them under prescription-only categories. However, recent deliberations suggest that the government may instead place these pills under Schedule K, allowing continued OTC access with added labeling requirements.
Gynecologists and public health experts have welcomed the move, emphasizing that timely access to emergency contraception is critical in preventing unintended pregnancies, especially among adolescents who may not be able to consult a doctor due to social or logistical barriers.
Key highlights from the policy update include
-
India may retain OTC status for levonorgestrel-based emergency contraceptive pills under Schedule K.
-
The decision follows rising adolescent pregnancy rates linked to early sexual activity and poor contraceptive awareness.
-
Gynecologists stress that OTC access empowers women and reduces stigma around reproductive health.
-
The pills will carry clearer warnings and dosage instructions to ensure safe usage.
-
Public health experts argue that restricting access could worsen reproductive health outcomes and increase unsafe abortions.
-
The move aligns with global best practices, where many countries allow OTC sale of emergency contraceptives.
The CDSCO is expected to finalize its position after reviewing stakeholder feedback and expert recommendations.
Sources: Moneycontrol, Mathrubhumi, News18.